Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 439

Sort by

Sort Order Select

Journal Articles

Interrogation of Individual CLL Loss-of-Function Lesions By CRISPR In Vivo Editing Reveals Common and Unique Pathway Alterations

Blood (2019) 134 (Supplement_1): 684.

https://doi.org/10.1182/blood-2019-127673

Published: 2019

Journal Articles

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Jason A. Dubovsky, PhD, Julie Rytlewski, PhD, Lin Yang, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 503.

https://doi.org/10.1182/blood-2019-127603

Published: 2019

Journal Articles

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Blood (2019) 134 (Supplement_1): 468.

https://doi.org/10.1182/blood-2019-128513

Published: 2019

Journal Articles

The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy

Paolo Milani, MD PhD, Marco Basset, MD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Jessica Ripepi, Margherita Bozzola, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1901.

https://doi.org/10.1182/blood-2019-130378

Published: 2019

Journal Articles

Early Response Observed in Pediatric Patients with Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma Treated with Sequential Chimeric Antigen Receptor T Cells

Wenqun Zhang, MD, Bo Hu, MD, Ling Jing, MD, Jing Yang, MD, Shan Wang, MD, Yang Liu, MD, Juan Du, MD, Yaoliang Ren, MD, Yonghong Zhang, MD

Blood (2019) 134 (Supplement_1): 1945.

https://doi.org/10.1182/blood-2019-125753

Published: 2019

Journal Articles

Phase I Study of Cord Blood Transplantation with Intra-Bone Marrow Injection of Mesenchymal Stem Cells

Tatsunori Goto, MD, Makoto Murata, MD PhD, Tetsuya Nishida, MD PhD, Seitaro Terakura, MD PhD, Sonoko Kamoshita, MD, Yuichi Ishikawa, MD PhD, Yoko Ushijima, MD PhD, Yoshiya Adachi, MD PhD, Katsuyoshi Kato, PhD, Akihiro Hirakawa, PhD, Satoshi Nishiwaki, MD PhD, Nobuhiro Nishio, MD PhD, Yoshiyuki Takahashi, MD PhD, Yoshihisa Kodera, MD, Tadashi Matsushita, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 2004.

https://doi.org/10.1182/blood-2019-122101

Published: 2019

Journal Articles

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Nathan Radakovich, BA, Mikkael A. Sekeres, MD MS, Cameron Beau Hilton, BA, Sudipto Mukherjee, MD PhD MPH, Jacob Shreve, MD MS, Yazan Rouphail, Rachel Shirley, Vera Adema, PhD, Hassan Awada, MD, Anjali S. Advani, MD, Cassandra M Kerr, MS, Yasunobu Nagata, MD PhD, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Aziz Nazha, MD

Blood (2019) 134 (Supplement_1): 2089.

https://doi.org/10.1182/blood-2019-126275

Published: 2019

Journal Articles

Deciphering the Role of Locally Disordered DNA Methylation on CLL Development In Vivo

Anat Biran, PhD, Helene Kretzmer, PhD, Shanye Yin, PhD, Leah Billington, BA, Fara Faye Regis, BS, Arman W. Mohammad, BA, Andreas Gnirke, Donna S Neuberg, ScD, Ruben D. Carrasco, MD PhD, Alexander Meissner, PhD, Catherine J. Wu, MD

Blood (2019) 134 (Supplement_1): 1737.

https://doi.org/10.1182/blood-2019-130744

Published: 2019

Journal Articles

Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience

James Yeung, MBBS, Ashlea Campbell, BSc MBBS FRACP FRCPA, Christian E Bryant, MBBS PhDFRACP FRCPA, Liane Khoo, MBBS PhDFRACP FRCPA, Scott Dunkley, MBBS FRACP FRCPA, Harry J Iland, MBBS FRACP FRCPA MHGSA, Stephen R Larsen, MBBS PhDFRACP FRCPA, Susan Moreton, MBBS FRACP FRCPA, Douglas E Joshua, BSc(Hons) MBBS DPhil FRACP FRCPA, Vinay Vanguru, MBBS FRACP FRCPA, Derek A McCulloch, BSc MBBChir PhDFRACP FRCPA, Danny Hsu, MBBS FRACP FRCPA, John Gibson, MBBS PhDFRACP FRCPA, P. Joy Ho, MBBS DPhil FRACP FRCPA, Christina Brown, MBBS PhDFRACP FRCPA

Blood (2019) 134 (Supplement_1): 2911.

https://doi.org/10.1182/blood-2019-131589

Published: 2019

Journal Articles

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

Danielle M. Brander, MD, John F. Seymour, MBBS, PhD FRACP, Thomas J. Kipps, MD PhD, Shuo Ma, MD PhD, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Michael Y. Choi, MD, Kathryn Humphrey, BSc, Abdullah Al Masud, PhD, Ruby Nandam, RN, MSN, Amanda Jacobson, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2019) 134 (Supplement_1): 3036.

https://doi.org/10.1182/blood-2019-126508

Published: 2019

Journal Articles

Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Blood (2019) 134 (Supplement_1): 864.

https://doi.org/10.1182/blood-2019-131476

Published: 2019

Journal Articles

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Beth A. Christian, MD, Ying Huang, MS, MA, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Jonathan E Brammer, MD, Narendranath Epperla, MDMS, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Farrukh T. Awan, MD, Kami J. Maddocks, MD, Kristie A. Blum, MD

Blood (2019) 134 (Supplement_1): 4082.

https://doi.org/10.1182/blood-2019-126242

Published: 2019

Journal Articles

The Effect of Hepatitis B Virus Antibody on Clinical Outcome and Prognosis in Patients with Diffuse Large B-Cell Lymphoma

Shunfeng Hu, Na Chen, MD, Kang Lu, MD PhD, Changqing Zhen, MD PhD, Yi Zhao, MM, Xin Wang, MD PhD

Blood (2019) 134 (Supplement_1): 4134.

https://doi.org/10.1182/blood-2019-127870

Published: 2019

Journal Articles

Alemtuzumab as First Line Treatment in Children with Familial Lymphohistiocytosis

Blood (2019) 134 (Supplement_1): 80.

https://doi.org/10.1182/blood-2019-124477

Published: 2019

Journal Articles

Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Blood (2019) 134 (Supplement_1): 4563.

https://doi.org/10.1182/blood-2019-125087

Published: 2019

Journal Articles

Exceptional Responders to Hypomethylating Agents in Myeloid Neoplasms: The Miami Experience

Venkata Thammineni, MD, Terrence J Bradley, MD, Felipe Novoa, NP, Deukwoo Kwon, Justin M. Watts, MD

Blood (2019) 134 (Supplement_1): 5107.

https://doi.org/10.1182/blood-2019-131006

Published: 2019

Journal Articles

Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study

Emilie Saucier, Florence Rabian, MD, Hélène Boutroux, MD, Marion Strullu, MD, Karine Morand, MD, Florian Chevillon, MD, Benoit Brethon, MD, Nicolas Boissel, MD PhD, Guy Leverger, MD, André Baruchel, MD

Blood (2019) 134 (Supplement_1): 5130.

https://doi.org/10.1182/blood-2019-131062

Published: 2019

Journal Articles

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Kelly S. Chien, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Michael Andreeff, MD PhD, Yesid Alvarado, MD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4240.

https://doi.org/10.1182/blood-2019-129598

Published: 2019

Journal Articles

Liposomal Daunorubicin/Cytarabine As a Bridge to Donor Lymphocyte Infusion or Allogeneic Stem Cell Transplantation for High-Risk Acute Myelogenous Leukemia

Daulath Singh, MD, Patrick Hagen, MD, Nasheed Hossain, MD, Scott E. Smith, MD PhD, Patrick J. Stiff, MD, Stephanie B. Tsai, MD MS

Blood (2019) 134 (Supplement_1): 5726.

https://doi.org/10.1182/blood-2019-129380

Published: 2019

Journal Articles

Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd

Jonathan C Poe, PhD, Dadong Zhang, PhD, Jichun Xie, PhD, Rachel A. DiCioccio, BS, Xiaodi Qin, MS, Jiyuan Fang, MS, Vincent T. Ho, MD, Jeremy J. Rose, MS, Steven Z. Pavletic, MD MS, Frances T. Hakim, PhD, Wei Jia, MD PhD, Amy N. Suthers, PhD, Mitchell E. Horwitz, MD, David A. Rizzieri, MD, William C. McManigle, MD, Nelson J. Chao, MD, Kouros Owzar, PhD, Stefanie Sarantopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 874.

https://doi.org/10.1182/blood-2019-130928

Published: 2019

NARROW

Interrogation of Individual CLL Loss-of-Function Lesions By CRISPR In Vivo Editing Reveals Common and Unique Pathway Alterations

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy

Early Response Observed in Pediatric Patients with Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma Treated with Sequential Chimeric Antigen Receptor T Cells

Phase I Study of Cord Blood Transplantation with Intra-Bone Marrow Injection of Mesenchymal Stem Cells

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Deciphering the Role of Locally Disordered DNA Methylation on CLL Development In Vivo

Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

The Effect of Hepatitis B Virus Antibody on Clinical Outcome and Prognosis in Patients with Diffuse Large B-Cell Lymphoma

Alemtuzumab as First Line Treatment in Children with Familial Lymphohistiocytosis

Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study

Exceptional Responders to Hypomethylating Agents in Myeloid Neoplasms: The Miami Experience

Azacitidine in Pediatric Hematologic Myeloid Malignancies: A Retrospective Study

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Liposomal Daunorubicin/Cytarabine As a Bridge to Donor Lymphocyte Infusion or Allogeneic Stem Cell Transplantation for High-Risk Acute Myelogenous Leukemia

Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only